BiomX Inc. (PHGE)
NYSEAMERICAN: PHGE · Real-Time Price · USD
4.510
-0.190 (-4.04%)
Dec 3, 2025, 4:00 PM EST - Market closed
BiomX Employees
As of December 31, 2024, BiomX had 57 total employees, including 52 full-time and 5 part-time employees. The number of employees decreased by 14 or -19.72% compared to the previous year.
Employees
57
Change (1Y)
-14
Growth (1Y)
-19.72%
Revenue / Employee
n/a
Profits / Employee
-$655,702
Market Cap
6.89M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57 | -14 | -19.72% |
| Dec 31, 2023 | 71 | 6 | 9.23% |
| Dec 31, 2022 | 65 | -54 | -45.38% |
| Dec 31, 2021 | 119 | 13 | 12.26% |
| Dec 31, 2020 | 106 | 20 | 23.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PHGE News
- 7 days ago - BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review - Benzinga
- 8 days ago - BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis - GlobeNewsWire
- 21 days ago - BiomX Inc. (PHGE) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates - GlobeNewsWire
- 6 weeks ago - BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways - GlobeNewsWire
- 3 months ago - BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis - GlobeNewsWire
- 4 months ago - BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates - GlobeNewsWire